Touhouche AT, Cassagne M, Bérard E, et al. - Researchers performed this prospective, single‐centre, real‐life study to characterize the incidence and nature of dupilumab‐induced ocular adverse events (OAEs) and to evaluate the potential predisposing factors. Participants in the study were adult AD patients treated with dupilumab, who were systematically examined by an ophthalmologist before and during treatment. Forty‐six patients with a median age of 41.1 years and a median initial SCOring Atopic Dermatitis of 46.0 were prospectively included. Most patients developed or aggravated dry eye disease, with superficial punctate keratitis. Findings suggested that patients with atopic dermatitis with eyelid eczema or dry eye disease symptoms may be referred to an ophthalmologist before beginning dupilumab to consider initiating preventive eye hydration measures. Additional multicentric and translational research are needed to better understand the pathophysiology of OAEs.